The pharmaceutical compositions for oral administration according to the invention
contain 0.5% to 20% of N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide
in microcrystalline form, and pharmaceutical excipients; they are formulated by
wet granulation.